MicroRNA is small, non-coding RNA molecules that prevent the production of specific proteins, regulating gene expression by tying the messenger RNA (MRNA). They play an important role in many biological processes, including development, cell discrimination, metabolism and disease progression. MicroRNA growth of the microRNA market is inspired by increasing prevalence of chronic diseases such as cancer and cardiovascular disorders, increasing interest in MIRNA, and progress in sequencing technologies and distribution systems that enable more accurate and efficient applications in diagnosis as diagnostic biomarkers, increasing intensity in MIRNA, and sequencing technologies and distribution systems.
Key Growth Drivers and Opportunities
Increasing Prevalence of Chronic Diseases: The growing prevalence of chronic diseases such as cancer, cardiovascular disorders, neurological conditions and diabetes is a major driver of the microRNA market, as these diseases often include abnormal gene expression patterns that help to regulate microRNA. MicroRNA works as both medical targets and clinical biometers due to their ability to affect multiple genes and routes simultaneously. As researchers and healthcare providers seek more accurate, initial detection equipment and personal treatment options, increasing demand for MIRNA-based diagnosis and medical science. This has expanded investment in MIRNA research and commercialization, which has increased the market.
Challenges
Despite its ability, the microRNA market faces several boundaries, including challenges in delivery methods, off-target effects and stability of miRNA molecules in biological environment. Ensuring safe, efficient and tissue-specific distribution is a major obstacle for medical applications. Additionally, the complexity of MIRNA interaction where a miRNA can regulate many genes and vice versa it is difficult to accurately predict the results. Regulatory uncertainty and high growth costs lead to further market growth, obstructing commercialization and clinical adoption.
Innovation and Expansion
Regulus Therapeutics to Be Acquired by Novartis, Promoting ADPKD MicroRNA Therapy
In April 2025, Novartis declared that it has reached a deal to buy Regulus Therapeutics, a publicly listed clinical-stage biopharmaceutical business located in San Diego that specializes in creating microRNA treatments. Farabursen, the main product of Regulus, is a possible first-in-class, next-generation oligonucleotide that targets miR-17 and is used to treat ADPKD. The agreement makes use of our strength and experience in renal illness and is entirely consistent with Novartis’ therapeutic area emphasis.
Farabursen is an experimental microRNA inhibitor that targets miR-17 with preferential kidney exposure in an effort to slow the evolution of ADPKD disease severity and decrease kidney size and cyst growth. The outcomes from the Phase 1b study demonstrated encouraging clinical effectiveness and safety, with consistent effects on height-adjusted total kidney volume (htTKV), a measure of progressing illness, and urine polycystin (PC), a biomarker of mechanistic response.
Inventive Sparks, Expanding Markets
The key players operating the MicroRNA market includes, Thermo Fisher Scientific, Illumina, QIAGEN, NEB, Takara Bio, Agilent Technologies, NanoString Technologies Inc., Bio-Rad Laboratories, Roche, GeneCopoeia, and others.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
